Optimi Health (OPTI) AI Stock Analysis

• Market Cap: C$28.07M
• Dividend Yield: N/A
• Average Volume (3M): 169.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: 65.16%
• EPS Growth: 33.18%
• Country: CA
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Agricultural Farm Products
• EPS (TTM): N/A
• Shares Outstanding: 96,776,920
• 10 Day Avg. Volume: 137,724
• 30 Day Avg. Volume: 169,715
• PEG Ratio: 0.24
• Price to Book (P/B): 5.70
• Price to Sales (P/S): 87.81
• P/FCF Ratio: -13.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.29 ▼(-10.63% Downside)
• Action: Reiterated Date: 02/20/26
• Date: Action: Reiterated 02/20/26

The score is primarily held down by weak financial performance (sharp revenue decline, negative gross profit, ongoing losses and cash burn, and higher leverage). Technicals are supportive with price above major moving averages and a positive MACD, but overbought readings (RSI/Stoch) add near-term risk. Valuation is constrained by negative earnings and no provided dividend yield.

Positive Factors

Regulated psychedelics and mushroom product focus

Operating in regulated psychedelics and functional mushroom segments positions the company in a structurally growing mental-health and wellness niche. Licensed production capability and product diversification across clinical and consumer channels offer durable market-entry advantages if regulation and demand expand.

Improving cash burn and narrowing losses

Management has reduced absolute cash outflows and narrowed operating losses year-over-year, reflecting cost control or more efficient operations. A sustained trend of improving cash flow strengthens runway and reduces near-term refinancing risk if maintained over the next several quarters.

Positive equity cushion

A positive equity base provides a tangible balance-sheet cushion to absorb ongoing losses and support working capital needs. While diminished from prior years, this capital buffer gives the company more time to execute commercialization or regulatory milestones without immediate insolvency risk.

Negative Factors

Very small and shrinking revenue base

A tiny and rapidly contracting top line undermines scalability and the ability to cover fixed costs. Persistent revenue weakness reduces optionality for strategic investments, makes margin recovery harder, and increases reliance on external financing for any meaningful growth initiatives.

Negative gross profit and persistent losses

Negative gross profit implies the core business is not generating positive unit economics. Continued deep operating and net losses signal structural margin problems that must be fixed via pricing, cost structure, or product mix changes before the business can sustainably generate positive operating cash flow.

Rising leverage reduces financial flexibility

Material increase in debt and a ~1.02 debt-to-equity ratio heighten refinancing and interest-service risk for an unprofitable company. Coupled with negative operating and free cash flow, higher leverage constrains strategic choices and raises the probability of dilutive financing or covenant pressure.

Optimi Health Business Overview & Revenue Model

Company Description

Optimi Health Corp. develops an integrated functional mushroom brand that focuses on the health and wellness food markets in Canada. The company also focuses on the cultivation, extraction, processing, and distribution of strains of functional mushroom. It offers a range of fungi varieties, which include Lions Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. The company was formerly known as 1251418 BC Ltd. and changed its name to Optimi Health Corp. in August 2020. Optimi Health Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Optimi Health generates revenue through multiple channels including subscription fees for its telehealth and online therapy services, which provide users with access to licensed mental health professionals. Additionally, the company may earn income from partnerships with employers and organizations that integrate its wellness programs into their employee health initiatives. The revenue model is further supported by potential licensing agreements for its proprietary digital health technologies and platforms. Strategic collaborations with healthcare providers and insurers can also contribute to revenue growth by expanding the reach of its services and enhancing its offerings.

Optimi Health Financial Statement Overview

Summary

Weak fundamentals: TTM revenue is very small and fell sharply (-54.6%), gross profit is negative, and the company remains deeply loss-making (EBIT about -4.65M; net income about -4.01M). Cash burn persists (TTM operating cash flow about -2.96M; free cash flow about -3.03M) and leverage increased materially (debt-to-equity ~1.02). Losses and cash burn have improved versus FY2024, but overall financial stability remains pressured.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small (193,601) and fell sharply (-54.6%), showing a weakening top-line trajectory. Profitability is extremely weak: gross profit is negative and operating results remain deeply loss-making (EBIT -4.65M; net income -4.01M), with very negative margins. While net losses have narrowed versus FY2024 (net income improved from -6.04M to about -3.71M in FY2025 annual), the business is still far from breakeven and revenue consistency remains a key concern.

Balance Sheet

Leverage has increased materially: total debt rose to ~6.7M in FY2025/TTM from ~2.75M in FY2024, pushing debt-to-equity to ~1.02, which reduces financial flexibility for a loss-making company. Equity remains positive (about 5.0M in TTM vs 6.6M in FY2025 annual), but it has trended down meaningfully from earlier years, reflecting ongoing losses and/or balance sheet pressure. Returns on equity are consistently negative (about -47% TTM), highlighting that the capital base is not currently generating profits.

Cash Flow

Cash generation is weak: TTM (Trailing-Twelve-Months) operating cash flow is negative (-2.96M) and free cash flow is also negative (-3.03M), indicating the business is consuming cash rather than funding itself. Cash burn has improved versus FY2024 (operating cash flow improved from -4.28M to -2.63M in FY2025 annual), but operating cash flow still does not cover the earnings deficit and remains negative. Reported free cash flow growth is positive in TTM, yet absolute free cash flow remains materially negative, keeping financing risk elevated.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	426.30K	389.85K	181.09K	80.72K	0.00
Gross Profit	-2.07M	270.91K	-157.04K	53.92K	-47.12K
EBITDA	-2.23M	-4.74M	-4.42M	-7.03M	-5.95M
Net Income	-3.71M	-6.04M	-5.19M	-7.38M	-6.04M
Balance Sheet
Total Assets	15.21M	14.55M	16.49M	16.82M	23.46M
Cash, Cash Equivalents and Short-Term Investments	1.15M	103.66K	1.34M	1.89M	12.43M
Total Debt	6.68M	2.75M	1.71M	157.58K	250.84K
Total Liabilities	8.64M	4.98M	3.28M	797.66K	2.40M
Stockholders Equity	6.57M	9.58M	13.21M	16.02M	21.07M
Cash Flow
Free Cash Flow	-2.72M	-4.43M	-4.41M	-11.73M	-10.96M
Operating Cash Flow	-2.63M	-4.28M	-3.60M	-4.58M	-6.02M
Investing Cash Flow	-88.38K	-154.02K	-706.02K	-3.15M	-9.19M
Financing Cash Flow	3.76M	3.19M	3.76M	1.19M	19.18M

Optimi Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Positive. The current price of 0.32 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.32, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 49.80 is Neutral, neither overbought nor oversold. The STOCH value of 20.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OPTI.

Optimi Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROMJ	55 Neutral	C$32.92M	3.70	7.78%	―	28.55%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OPTI	47 Neutral	C$28.07M	-4.90	-44.37%	―	65.16%	33.18%
AVCN	46 Neutral	C$23.88M	-5.08	-77.67%	―	2.41%	74.61%
LABS	45 Neutral	C$29.45M	-3.68	-19.10%	―	18.06%	34.58%
PCLO	44 Neutral	C$7.69M	5.19	―	―	15.64%	58.47%
DOSE	41 Neutral	C$19.12M	-4.62	―	―	95.76%	22.56%

Optimi Health Corporate Events

Optimi Health Advances Psilocybin Rollout for Treatment-Resistant Depression in Australia

Optimi Health has begun early clinical rollout of its naturally derived 5 mg psilocybin capsules for patients with treatment-resistant depression in Australia, marking the first patients of 2026 treated outside sponsor-led clinical trials under the country’s regulated framework. The products are manufactured in Canada to TGA quality standards and supplied via an Australian pharmacy partner, with administration handled by Authorised Prescribers under national rules.

The company is now supplying both psilocybin for depression and MDMA for PTSD into Australia’s regulated medical framework, signalling growing clinical adoption of psychedelic therapies within the Authorised Prescriber Scheme. Treatment data and patient-reported outcomes are being captured in a national registry in partnership with Australian National University, underscoring a structured, data-driven approach that may influence future policy, clinical practice, and broader market acceptance of psychedelic-assisted therapies.

The most recent analyst rating on (TSE:OPTI) stock is a Sell with a C$0.28 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health Expands Australian Footprint With Psilocybin Export for TRD

Optimi Health has completed the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for use in patients with treatment-resistant depression under the country’s Authorised Prescriber Scheme. This marks the company’s second psychedelic drug product in the Australian market, joining its 40 mg and 60 mg MDMA capsules for PTSD, and underscores its fully integrated production model and growing role in regulated psychedelic-assisted therapy.

The new psilocybin capsules will be available through authorised clinics, including programs that may be reimbursed by Australia’s Department of Veterans’ Affairs, potentially broadening patient access and supporting real-world data collection through a national patient registry with the Australian National University. By leveraging its Drug Establishment Licence to export pharmaceutical-grade products internationally, Optimi strengthens its position in the emerging medical psychedelics sector and deepens its commercial foothold in Australia’s regulated therapeutic framework.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.36 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health Expands MDMA-Assisted PTSD Treatments Across Australian Clinics

Optimi Health has begun the first MDMA-assisted treatments of 2026 at an expanded network of authorized clinics in Australia, under the country’s Authorised Prescriber Scheme. The company is supplying its 40 mg and 60 mg MDMA capsules directly to clinics, maintaining manufacturing oversight and cost control while supporting a scalable model for regulated psychedelic therapy.

The rollout aligns with growing institutional support in Australia, including a veterans rehabilitation plan that backs psychedelic-assisted therapy for PTSD. With real-world evidence on patient outcomes being collected by the Australian National University and no serious adverse events reported in Scheme data as of late 2025, the initiative strengthens Optimi’s position in the emerging market for MDMA-assisted PTSD treatment, particularly among veterans and first responders.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health Ships MDMA to Australia for PTSD Treatment Programs

Optimi Health has completed its first MDMA export of 2026 to Australia, shipping 1,000 standardized 60 mg capsules for use in authorized clinical programs treating Post-Traumatic Stress Disorder under the country’s Authorised Prescriber Scheme. The batch, sufficient for more than 300 MDMA-assisted therapy sessions, strengthens Optimi’s role in Australia’s emerging psychedelic treatment market and supports extensive real-world evidence gathering by the Australian National University, while its Australian pharmacy partner distributes the product to clinics nationwide under existing reimbursement and regulatory frameworks aimed at veterans and other PTSD patients.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health Begins 2026 Shipments of MDMA and Psilocybin Capsules to Australia

Optimi Health has completed its first 2026 production cycle of MDMA and psilocybin capsules for the Australian market, with 1,000 MDMA capsules (60 mg) and 1,000 naturally derived psilocybin capsules (5 mg) now fully packaged, labeled and batch-released under its Health Canada Drug Establishment Licence. Following issuance of Australian import permits, the GMP-compliant capsules have been approved for import under Australia’s Authorised Prescriber Scheme, positioning Optimi to continue and potentially expand supply into the country’s regulated healthcare system at a time when PTSD and treatment-resistant depression remain significant unmet medical needs affecting millions of Australians.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health Grants Equity Incentives and Launches New Investor Awareness Campaigns

Optimi Health has approved an equity incentive grant comprising 850,000 stock options and 555,000 restricted share rights to directors, officers, employees, and key individuals, with the aim of aligning compensation with long-term growth and retention objectives. The company has also engaged Diamond Equity Research for independent research coverage and Native Ads for a digital investor awareness campaign of up to US$350,000 over as long as 24 months, moves intended to broaden market visibility for its regulated MDMA and psilocybin product portfolio and potentially strengthen its positioning among investors in the emerging psychedelic pharmaceuticals sector.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health to Court Institutional Investors at Sidoti Micro-Cap Conference

Optimi Health Corp. will present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026, where CEO Dane Stevens is scheduled to host a virtual presentation and one-on-one meetings with institutional investors. By engaging directly with the investment community at a dedicated micro-cap forum, the company is seeking to raise its profile among institutional investors and potentially broaden its shareholder base as it advances its position in the emerging market for regulated psychedelic-based mental health treatments.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Optimi Health Adds Risk Management Veteran Jason Mosberian to Board

Optimi Health has appointed Jason Mosberian to its board of directors, replacing outgoing director Jonathan Schintler, with the move subject to Canadian Securities Exchange approval. Mosberian, a CPA and Senior Vice President and Partner at BFL Canada, brings more than a decade of experience in risk management and insurance across manufacturing, distribution and life sciences, bolstering governance and risk oversight at the psychedelic drug manufacturer as it expands its regulated pharmaceutical operations.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.